Previous 10 | Next 10 |
NEW YORK, NY / ACCESSWIRE / December 12, 2022 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against NeoGenomics, Inc. ("NeoGenomics" or the "Company") (NASDAQ:NEO) and reminds investors of the February 6, 2023 deadline to seek the role of l...
Summary What started as a seemingly innocuous leadership transition at one of the country's leading molecular diagnostic firms, NeoGenomics, Inc., has evolved into something much more chaotic. After the departure of former NeoGenomics, Inc. CEO and company veteran Douglas VanOort last y...
New York, New York--(Newsfile Corp. - December 7, 2022) - Levi & Korsinsky, LLP notifies investors in NeoGenomics, Inc. ("NeoGenomics" or the "Company") (NASDAQ: NEO) of a class action securities lawsuit. The lawsuit on behalf of NeoGenomics investors has been commenced in the the United S...
Jeffrey S. Sherman Appointed Chief Financial Officer FT. MYERS, FL / ACCESSWIRE / December 5, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, today announced that Jeffrey S. Sherman will join the company as Chief Financial ...
FN Media Group Presents USA News Group News Commentary Vancouver, BC –November 30, 2022 – USA News Group – A new study has revealed that women diagnosed with benign breast disease through screening have an almost double risk of acquiring breast cance...
Data presented at this year's San Antonio Breast Cancer Symposium builds on strong base of evidence supporting promise of RaDaR in helping prevent recurrence and improving outcomes FT. MYERS, FL / ACCESSWIRE / November 21, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of onc...
Program leverages NeoGenomics' expertise to provide ovarian cancer patients critical insights to ensure they are getting the right treatment FT. MYERS, FL / ACCESSWIRE / November 18, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract resear...
Summary Invitae Corporation has one chance to leverage itself into profitability in the next 12 - 18 months. The cash balance is barely enough to cover the company's cash burn, even if it achieves its 2023, leaving little room for error. Executing the "realignment plan" must b...
Shares of NeoGenomics (NASDAQ: NEO) jumped 53.9% this week, according to data from S&P Global Market Intelligence . The cancer diagnostic company's stock closed last Friday at $7.31 a share and then opened on Monday at $7.41. It rose throughout the week and hit its weekly hi...
Summary CareDx reported lackluster performance in the third quarter, with core testing revenue down by 2.5%, mirroring intensifying competitive dynamics impacting its pricing power. Competitive dynamics are exacerbated by the company's expansion in niche markets with structurally ...
News, Short Squeeze, Breakout and More Instantly...
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced that it will report its second quarter 2024 financial results after the close of the U.S. financial markets on Monday, July 29, 2024. Company management will host a webcast and conference call at 4:30 ...
2024-06-23 10:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced that Fort Myers’ Mayor, Kevin Anderson, will be dedicating June as NeoGenomics’ Commitment to Cancer Month to honor cancer survivors and those currently living with cancer. Headquartered in...